Vescor Therapeutics Inc., is an immuno-oncology company that is developing new therapies that modulate endoplasmic reticulum (ER) stress response pathways in the tumor microenvironment. Chronic activation of this stress response is linked to poor outcomes in multiple cancers, such as ovarian cancer, triple-negative breast cancer, pancreatic adenocarcinoma and glioblastoma. The company was founded based on intellectual property generated from Weill Cornell Medicine and is developing small molecule therapeutics that inhibit the enzyme IRE1α.
